


Volume 20 No 10 (2022)
Download PDF
COVID 19 Effects on Patients with Compensated Cirrhosis
Usama Mohamed Basha, Alaa Ahmed Farag, Mohamed Ali Ramadan, Ashraf Khalifa Elnagar, Ahmed Esmail Ahmed
Abstract
The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral
infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged
in Wuhan, China and spread around the world. Genomic analysis revealed that SARS-CoV-2 is
phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore
bats could be the possible primary reservoir.The intermediate source of origin and transfer to
humans is not known, however, the rapid human to human transfer has been confirmed widely.
There is no clinically approved antiviral drug or vaccine available to be used against COVID-19.
However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical
trials, resulted in clinical recovery.The liver, the largest internal organ in the body, is essential in
keeping the body functioning properly. It removes or neutralizes poisons from the blood, produces
immune agents to control infection, and removes germs and bacteria from the blood. It makes
proteins that regulate blood clotting and produces bile to help absorb fats and fat-soluble vitamins.
Several studies have shown a significant risk of mortality in patients with cirrhosis and in liver
transplantation recipients.2, 3, 4 The severity of presentation and risk of mortality is more in
patients with decompensated cirrhosis.5,6 COVID-19 had lead to a significant decrease in number
of liver transplant surgeries being performed, which would lead to an increased wait list mortality
in these patients
Keywords
COVID 19, Compensated Cirrhosis
Copyright
Copyright © Neuroquantology
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the Neuroquantology are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJECSE right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.